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Abstract
Background: Pandemic influenza represents a major threat to global health. Vaccination is the most economic and effective
strategy to control influenza pandemic. Conventional vaccine approach, despite being effective, has a number of major
deficiencies including limited range of protection, total dependence on embryonated eggs for production, and time
consuming for vaccine production. There is an urgent need to develop novel vaccine strategies to overcome these
deficiencies.
Methodology/Principal Findings: The major objective of this work was to develop a novel vaccine strategy combining
recombinant haemagglutinin (HA) protein and a master cell (MC) activator C48/80 for intranasal immunization. We
demonstrated in BALB/c mice that MC activator C48/80 had strong adjuvant activity when co-administered with
recombinant HA protein intranasally. Vaccination with C48/80 significantly increased the serum IgG and mucosal surface IgA
antibody responses against HA protein. Such increases correlated with stronger and durable neutralizing antibody activities,
offering protection to vaccinated animals from disease progression after challenge with lethal dose of A/California/04/2009
live virus. Furthermore, protected animals demonstrated significant reduction in lung virus titers, minimal structural
alteration in lung tissues as well as higher and balanced production of Th1 and Th2 cytokines in the stimulated splenocytes
when compared to those without C48/80.
Conclusions/Significance: The present study demonstrates that the novel vaccine approach of combining recombinant HA
and mucosal adjuvant C48/80 is safe and effective in eliciting protective immunity in mice. Future studies on the mechanism
of action of C48/80 and potential combination with other vaccine strategies such as prime and boost approach may help to
induce even more potent and broad immune responses against viruses from various clades.
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Introduction
Pandemic influenza represents a major threat to global health as
novel pathogenic strains can potentially emerge and spread among
humans anytime and anywhere around the world. In April 2009,
while many of the experts worried about cross-species as well as
human to human transmission of the highly pathogenic avian
influenza A (HPAI) H5N1 in Asia, the outbreak of a novel strain of
H1N1 influenza A virus emerged in Mexico instead. This novel
strain, also referred to as ‘‘swine flu’’, is the recombinant of a
previous triple reassortment of bird, pig, and human influenza A
viruses that has further recombined with a Eurasian pig influenza
A virus [1,2]. Unlike most strains of influenza A, the pandemic
H1N1 does not disproportionately infect adults older than 60
years. In fact, people in this age group showed some trend in
resisting infection or had a slower rate of disease progression
[3,4,5]. A fraction of young and healthy persons, however,
developed severe acute respiratory distress syndrome. Further-
more, this novel H1N1 strain demonstrated exceedingly high
transmission efficiency among humans throughout the world.
Thus, by June 11, 2009, the World Health Organization declared
the outbreak of the novel H1N1 to be a pandemic.
Vaccination is the most economic and effective strategy to
control influenza pandemic. Conventional influenza vaccines use
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by inducing neutralizing antibodies against the highly variable
surface glycoproteins, hemagglutinin (HA) and neuraminidase
(NA). In general, these vaccines are highly effective in protecting
humans from infection and significantly reduce the symptoms of
disease [6]. However, a number of major deficiencies are clearly
recognized with the current vaccines. First, the breadth of
immunity is rather limited and its protective functions are only
in the context of infecting viral strains that closely resemble the
antigenic specificities of those in the vaccines. As antigenic drift
frequently occurs for the virus, annual surveillance and production
of new vaccines is required. Second, the production of vaccines is
entirely dependent on embryonated eggs. This approach,
developed more than half century ago, is time-consuming and
can potentially be handicapped by insufficient supplies of eggs
which could happen in particular when epidemic of HPAI
occurred. The vaccine normally takes at least 6 months to
produce and distribute once a potential pandemic strain has been
identified. This is exemplified by the vaccine against 2009 H1N1
‘‘swine flu’’ which was not made available until August,
approximately half a year after the identification of the novel
virus [7,8,9,10,11]. In the mean time, the virus continued to
spread around the world. It could be imagined that if the virus was
deadly, the consequences would be disastrous. Furthermore, the
egg-based approach, at least in theory, may fail to adapt the virus
to produce sufficient quantities for mass use. During adaption
process, the immunogenicity of the viral epitopes could also be
altered so that the antibodies induced by them may be different
from those against non-culture wild-type strains. Taken together,
all these provide a strong argument for the urgent need to develop
alternative vaccine strategies to overcome the major deficiencies
associated with the conventional vaccine approach.
In June 17, 2003, the US Food and Drug Administration (FDA)
approved a novel vaccine for influenza called FluMist, which is the
first and the only live attenuated vaccine for influenza available
outside of Europe then [12,13]. The idea for this novel vaccine is
at least two-fold. First, as influenza virus infects the upper
respiratory tract and cause a contagious acute respiratory disease,
vaccine should at least generate sufficient immune responses at the
mucosal surfaces to provide the first line of defense against the
initial viral attack. Second, the needle-free approach involving
nasal spray provides a much easier way for immunization and
hence increases the access to the general public. While this novel
approach has several obvious advantages over the conventional
approaches, it also faces the same drawbacks similar to all of the
other live attenuated vaccines. The major ones include its nature
of instability which may result in mutant back to the pandemic
strain, and potential risk of development of novel chimeric strains
between the vaccine and wild-type viruses.
The aim of this study is to develop a safe and effective influenza
vaccine which can overcome the shortcomings and, to improve on
the strength of above-mentioned vaccine approaches at the same
time. In particular, we focus on the development of recombinant
HA protein-based vaccine in conjunction with a novel adjuvant
(C48/80) targeting mast cells (MC) at the mucosal surface in the
nostrils. Compound 48/80 (C48/80) is a polymer that has long
been known for its role in activating MC, and so named MC
activator [14,15,16]. Its role as an effective adjuvant, however, was
only identified recently in the context of protection against anthrax
lethal toxin challenge as well as vaccinia virus infection in vivo [17].
It has also been shown that immunized wild-type mice with C48/
80 mixed with a low dose of protective antigen (PA) from Bacillus
anthracis resulted in a robust increase in IgG antibody [17]. Such
response seems to operate through the activation of dendritic cells
(DCs) and mast-cell derived TNF [17], stored in and then released
from the granules to mobilize lymphocytes and DCs [17,18]. The
working hypothesis for MC-activator as an adjuvant is that the
activation-induced release of inflammatory mediators can lead to
activation of DCs containing the immunized antigens and further
migration to the draining lymph nodes, thereby reinforcing the
antigen-specific immune responses [17,18,19,20,21].
In this report, we present evidence that 2009 H1N1 HA-based
subunit vaccine together with C48/80, when used to immunize
mice through the intranasal route, evoked significant increases in
HA-specificserum IgG aswell mucosalIgAresponsesinthe nostrils,
lung, vagina and gut. Such increases were for both binding activities
to HA proteins as well as neutralizing activities against live 2009
H1N1 virus. In contrast, no significant increases in serum total and
HA-specific IgE was found. Furthermore, this vaccine approach
elicited protective immunity against challenge with lethal dose of
2009 pandemic H1N1 influenza. Lastly, the antibody responses
induced through our novel approach was comparable in magnitude
and duration to that induced by cholera toxin, which has been
considered to be a gold standard for mucosal adjuvants.
Collectively, our findings indicate that the novel vaccine approach
of combining recombinant HA and mucosal adjuvant C48/80 is
safe and effective in eliciting protective immunity in mice. It offers
the type of influenza vaccine that we urgently need with
unprecedented speed and efficacy. The implication of our findings
for future vaccine development in humans is also discussed.
Materials and Methods
Reagents
The extracellular domain of H1N1 (A/California/04/2009)
HA protein containing a His-tag at the C-terminal was produced
in 293 cells and purified through affinity chromatograph (Sino
Biological Inc. Beijing, China) The protein, comprising 523 amino
acid residues, was secreted from the transfected cells with a
predicted molecular mass of 59 kDa. As a result of glycosylation, it
migrated as an approximately 75–80 kDa band on SDS-PAGE
under reducing conditions (data not shown). Cholera toxin (CT)
and compound 48/80 (C48/80) were purchased from Sigma-
Aldrich (Beijing, China).
Ethics Statement, immunization and challenge
All procedures for animal use and care were approved by the
Institutional Committee on Laboratory Animals at CAMS/
PUMC and Tsinghua University (2010-ZhangLQ-ADV). Four-
week-old female BALB/c mice were purchased form Institute of
Laboratory Animal Sciences at Chinese Academy of Medical
Science (CAMS) and Peking Union Medical College (PUMC).
Four groups of mice, each consisted of 28 (Fig. 1), were
anesthetized with isoflurane followed by intranasal immunization
with either PBS for negative control, 9 mg recombinant HA alone
or HA plus adjuvants C48/80 (10 mg) or CT (0.1 mg) in a total
volume of 15 ml (7.5 ml per nostril). The final dilutions for HA or
HA plus adjuvant were made in saline. The immunization scheme
and sample collection are as shown in Fig. 1. All mice were primed
on day 0, and then boosted on day 7 and 14 days afterwards.
Twenty mice from each group were challenged intranasally one
week after the second boost (21 days after immunization) with
1610
6 TCID50 A/California/04/2009 live virus. The virus was a
mouse-adapted strain with one amino acid change and became
lethal on mice [22,23]. The virus was initially propagated in 10-
day-old embroynated hens’ eggs and titered in Madin-Darby
canine kidney (MDCK) as previously described [24]. Ten mice in
each challenged group were monitored daily for signs of diseases,
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ten mice were euthanized at 5 day post challenge and whole lung
tissue samples were collected separately for viral nucleic acid
quantification and pathological investigation as previously de-
scribed [22,23]. Three mice from each group were used to collect
spleen samples for cytokine profiling (see below) right before
intranasal inoculation of live virus challenge. Five mice from each
group were used to monitor the long-term antibody responses
against HA for up to day 76 after first immunization (Fig. 1).
Serum, vaginal and fecal samples were collected on day 0, 7, 14
and 21. Lung and nasal washes were collected on day 21. Serum
collections were also done on day 45 and 76 for monitoring
antibody responses (Fig. 1). All mice were anesthetized and blood
samples were collected from mice tail into 1.5 ml centrifuge tubes
by vein puncture. After clotting overnight at 4uC, the blood was
centrifuged at 2500 rpm for 30 min. The serum was transferred to
a new 1.5 ml centrifuge tube and stored at 280uC until time of
testing. A total of 100 ml PBS was used for vaginal washing. PBS
stayed at least 10 sec in the mouse vagina for each washing and
was washed at least 3 times for each mouse. Vaginal lavage sample
was centrifuged at 13,000 rpm for 30 min, the supernatant was
transferred to a new 1.5 ml centrifuge tube and stored at 280uC.
Fresh fecal sample from each mice were also collected into a
1.5 ml centrifuge tube with 100 ml PBS and were vortexed severely
until thoroughly mixed. The mixture was centrifuged at
13,000 rpm for 30 min and the supernatant was transferred into
a new 1.5 ml centrifuge tube and stored at 280uC. Mice lung and
nasal washes were collected as previously described [25]. For lung
washes, mice trachea and lungs were removed after euthanized,
and were washed 3 times by 2 ml of PBS containing 0.1% BSA.
For nasal washes, mice were decapitated and lower jaws were
excised. 1 ml of PBS containing 0.1% BSA was injected into the
posterior opening of the nasopharynx of mice 3 times to collect the
nasal washes. All washes were centrifuged to removing cellular
debris and the supernatant were stored at 280uC for later use.
Histology
For pathological examination, lung samples were fixed in 10%
formalin, embedded in paraffin and sectioned. Conventional
hematoxylin-eosin (H&E) staining was conducted on serial 4 mm
tissue sections and examined under the light microscope by a
pathologist blinded to the experimental groups.
Measurement of binding antibodies against HA
Binding antibody was measured using conventional ELISA
technique. In brief, 96-well plates were coated with 100 ml/well of
H1N1 HA protein at 1 mg/ml in carbonate coating buffer
overnight at 4uC. After blocking with 10% FBS and 0.05%Tween
in PBS, the plates were washed twice with 0.05% Tween in PBS.
Serially diluted serum, nasal and lung washes, and vaginal and
fecal samples in PBS, were added at 100 ml per well and incubated
for 1 hour at 37uC. After 3 washes, horseradish peroxidase (HRP)-
conjugated goat anti-mouse IgG antibodies (Promega, US), anti-
IgA antibodies and anti-subclass IgG1, IgG2a, IgG2b, IgG3
antibodies (Santa Cruz, US) were added and incubated at 37uC
for another hour. After extensive washes, 50 ml of HRP-substrate
3,39,5,59-tetramethylbenzidine (TMB) was added, incubated for 5
minutes, and stopped by adding 50 ml1MH 2SO4. Samples were
measured at an absorbance of 450 nm. End-point titer were
recorded as the reciprocal log2 dilution of the last sample whose
OD was at least 3-fold higher than that of the corresponding naive
sample.
Measurement of total and HA-specific IgE in immunized
mice
Mouse serum total IgE were detected by Mouse IgE ELISA Set
(BD Biosciences, USA). Briefly, 96-well plates were coated with
100 ml/well of capture antibody diluted in coating buffer ( 0.1 M
Sodium Carbonate, PH 9.5 ) at 1:250 dilution and incubated
overnight at 4uC. After blocking with assay diluent (PBS with 10%
Figure 1. Immunization and sample collection scheme. Four groups of mice, each consisted of 28, were immunized with either PBS,
recombinant HA alone, HA plus C48/80 (10 mg) or CT (0.1 mg). Twenty mice were used for challenge with lethal dose of A/California/04/2009 live virus
on 21 days after initial immunization and monitored for diseases (n=10) and viral and pathological investigation in lung tissues (n=10). The
remaining eight were used for either cytokine production from stimulated spleenocytes (n=3) or long-term antibody response (n=5).
doi:10.1371/journal.pone.0019863.g001
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and kept in 37uC for 2 hours. IgE standard was prepared at two-
fold dilutions in assay diluents starting at 50 ng/ml. Following
incubation, plates were washed and detection antibody (1:1000)
with enzyme reagent (1:250) diluted in assay diluents were added
at 100 ml/well. After incubation at 37uC for 1 hour, 50 ml
substrate TMB was added, incubated for 5 minutes, and stopped
by adding 50 ml1MH 2SO4. The plate was read at 450 nm and
OD values were compared to the standard curve to determine the
IgE concentration of each serum. The method for determining
antigen-specific IgE titers was similar to the total IgE ELISA
except that the coating protein was H1N1 HA at 1 mg/ml in
carbonate coating buffer.
Measurement of neutralizing antibodies against A/
California/04/2009 live virus
Neutralizing antibodies were measured by using a neutralization
assay based on MDCK cell culture. In brief, MDCK cells were
seeded at 1.5610
4 cells/well in 96-well culture plates and
incubated overnight at 37uC. All mouse serum samples were
inactivated at 56uC for 45 min. Serial two-fold dilutions of each
serum samples were mixed separately with 100 TCID50 of A/
California/04/2009 live virus and incubated at 37uC for 2 h. The
mixture was then added directly to MDCK cells in the 96-well
culture plates, and the neutralizing titers of mouse serum were
assessed based on presence or absence of cytopathic effect (CPE) 3
days post infection. Neutralization antibodies titers were deter-
mined as the reciprocal of the serum dilution that decreased by
50% the number of CPE wells formed by the live virus and the 50
percent endpoints were computed by Reed-Muench method [26].
Viral load measurement in lung by real-time PCR
Total RNA was isolated from mice lung tissues by using the
RNeasy Mini Kit (Qiagen, US). RNA was dissolved in 30 ml
diethyl pyrocarbonate-treated water and stored at 280uC. First-
strand cDNA was synthesized by using random hexamers
containing 200 Unit of Superscript III reverse transcriptase
(Invitrogen, US). The real-time relative quantitative PCR assays
were performed on ABI PRISMH7500 in a total of 20 ml volume
containing 2 ml cDNA, CSqPCR Master Mix (Shanghai Chaoshi
Bio Technologies Co., Ltd.), pair primers and specific Taqman
probe for either H1N1 or mouse GAPDH transcripts. The
sequences for primers and probes are list as follows: H1N1-F:59-
GTG CTA TAA ACA CCA GCC TYC CA -39; H1N1-R:59-
CGG GAT ATT CCT TAA TCC TGT RGC -39 H1N1-Probe:
59-FAM-CA GAA TAT ACA TCC RGT CAC AAT TGG ARA
A-BHQ-39; GAPDH-F:59-GCA CAG TCA AGG CCG AGA A-
39, GAPDH-R:59-CCT CAC CCC ATT TGA TGT TAG TG-
39, GAPDH-Probe: 59-FAM-CATC ACC ATC TTC CAG GAG
CGA GAC C-BHQ1-39. Thermal cycling was conducted under
the following conditions: 95uC for 10 min, followed by 40 cycles of
95uC for 30s and 60uC for 40s. Lung relative viral load was
normalized to H1N1 RNA loading for each sample using the
GAPDH RNA as an internal standard. The relative quantity of
lung H1N1 virus RNA was given as 2
2DDCT. DDCT was
calculated as follows: DDCT=DCT(target)2DCT(reference) [27].
Measurement of cytokine release by stimulated
splenocytes in mice
Three mice from each group were used to study cytokine
profiles from stimulated splenocytes. Mice were euthanized one
week after the second boost (21 days after immunization),
coinciding with the time right before virus challenge (see above).
The spleens were immediately collected and made into single cell
suspension. Cells were washed three times and plated in 48 well
culture plates at 2.5610
6 cells/well with RPMI 1640 medium ,
10% heat-inactivated fetal bovine serum (FBS), and 1% penicillin
and streptomycin. Five micrograms (5 mg) of H1N1 HA protein
was then added to each well to yield a final concentration of 5 mg/
ml. These cell culture plates were incubated in 5% CO2 incubator
at 37uC and supernatants were harvested 72 hours later. Collected
supernatant was first centrifuged to remove cell debris and then
stored at 280uC until use. The cytokines in the supernatant
including IL-2, IL-4, IL-6, IL-17, TNF and IFN-alpha were
determined by flow cytometry using a mouse Th1/Th2/Th17
CBA Kit (BD Biosciences, US).
Statistic analysis
We used unpaired two sample t-test to compare serum IgG,
lung, nasal washes, vaginal and fecal IgA , as well as relative viral
load in lung tissue after challenge between groups. A value of
p#0.05 was considered statistically significant. ANOVAs for
multiple comparisons were performed for comparison of param-
eters between groups for serum IgG subclasses. All statistic analysis
was performed using GraphPad Prism 5 (GraphPad Software Inc.,
San Diego CA, www.graphpad.com.).
Results
MC activator C48/80 significantly increases systemic and
mucosal antibody responses against HA protein through
intranasal immunization
To investigate whether C48/80 could be used as an adjuvant
for influenza recombinant HA protein, we first immunized 4 mice
each with 1 mg, 3 mg, or 9 mg recombinant HA coupled with 10 mg
C48/80 on day 0, 7 and 14 through intranasal route. Fig. 2
Figure 2. Geometric mean titers (GMT) for serum anti-HA
antibody responses after immunization with three doses (1 mg,
3 mg, or 9 mg) of recombinant HA together with C48/80, and
compared with HA alone (9 mg) or plus CT. The numbers on the
bar indicate the actual value of GMT.
doi:10.1371/journal.pone.0019863.g002
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binding antibodies against HA protein for the 3 dose groups on
day 21. It is clear that recombinant HA protein (9 mg) alone
induced detectable but borderline serum binding antibody with
GMT of 53. However, the same amount of HA protein
administered together with C48/80 induced significantly higher
levels (P,0.05) of binding antibody with GMT reaching 128,000,
which was more than 3 logs higher compared to that with HA
alone. In addition, as the dose of HA decreased from 9 ug to 3 mg
and 1 mg , there was corresponding decline in binding antibody
with GMT at 6,400 and 3,200 respectively. Furthermore, levels of
binding antibody in the 9 ug HA plus C48/80 group (128,000)
was comparable to that in the 9 ug HA plus CT group (107,634).
Lasting, we also measured the total IgE and HA-specific IgE
antibody concentration in the immunized mice. No significant
Table 1. Concentration of serum total IgE (n=4/group).
Group Serum total IgE (ng/ml)
PBS 37.06622.25
HA 9 mg 76.36643.78
HA 1 mg+c48/80 10 mg 78.27638.9
HA 3 mg+c48/80 10 mg 104.1641.45
HA 9 mg+c48/80 10 mg 83.99615.02
HA 9 mg+CT 0.1 mg 66.58631.24
doi:10.1371/journal.pone.0019863.t001
Figure 3. Geometric mean titers (GMT) for serum (A) and mucosal (B: vaginal; C: fecal; D: lung; and E: nasal) anti-HA antibody
responses of four groups of animals (n=4–10 per group) measured on 21 days after initial immunization by ELISA. Bars represent the
GMT of all animals in each group with error bars representing the 95% confidence. The numbers on the bar indicate the actual value of GMT. Star (*)
indicates the significant difference in antibody titers between HA alone and HA plus C48/80 or plus CT (p,0.05).
doi:10.1371/journal.pone.0019863.g003
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HA alone (76.36643.78 ng/ml) or with C48/80 (83.996
15.02 ng/ml) or CT (66.58631.24 ng/ml) (Table 1). Dose
differences in recombinant HA did not resulted in discernable
differences in total IgE concentration. In particular, no HA-
specific IgE was detected in any of the immunized group,
suggesting that MC activator C48/80 did not induce IgE
production or IgE-associated allergic and hypersensitivity reac-
tions. We have therefore chosen the 9 ug HA group for more
detailed immunologic characterization and challenges experiment
with A/California/04/2009 live virus.
We immunized 28 mice each with either 9 mg recombinant HA
alone, with C48/80 (10 mg), with PBS or CT (0.1 mg) in a total
volume of 15 ml (7.5 ml per nostril) on day 0, 7, and 14 (Fig. 1).
Fig. 3A demonstrates GMT of serum IgG binding antibodies
against HA protein among the four groups one week after the final
immunization (day 21 after initial immunization). Recombinant
HA protein alone induced detectable but borderline serum
binding antibody with GMT of 49. However, the same amount
of HA protein administered together with C48/80 induced
significantly higher levels (P,0.05) of binding antibody with
GMT reaching 90,510, which was more than 3 logs higher
compared to that with HA alone. Furthermore, levels of binding
antibody in the HA plus C48/80 group was comparable to that in
the HA plus CT group (13,7187), suggesting MC activator C48/
80 had similar potent adjuvant effect at the mucosal surface as that
of CT, which is considered to be a gold standard for mucosal
adjuvants. The GMT for PBS only group was about 4 (Fig. 3A).
In addition, vaginal lavage and fecal extracts as well as lung and
nasal washes from the four groups were also tested for HA-specific
IgA binding antibody one week after the final immunization (day
21 after initial immunization). Fig. 3B,3C, 3D, and 3E show that,
similar to IgG binding antibodies, intranasal immunization with
HA protein plus C48/80 induced significantly higher levels
(P,0.05) of IgA binding antibody compared to that with HA
alone at the vaginal and gastrointestinal as well as nasal and lung
surfaces. The GMT for the HA plus C48/80 group was 43 for
vaginal lavage (Fig. 3B),7 for fecal extracts (Fig. 3C), 11 for lung
and nasal washes (Fig. 3D and 3E), while that for the HA alone
and negative control group were under the detection limit.
Furthermore, such levels of IgA antibody responses were
equivalent to that induced by CT which was 98 for vaginal
lavage,12 for fecal extracts, 11 for lung washes (Fig. 3D) and 32 for
nasal washes (Fig. 3E). These findings indicate that MC activator
C48/80 can significantly increase the immunogenicity of HA
protein both systemically and at the mucosal surfaces, and its
adjuvant effect is comparable to that of CT.
MC activator C48/80 significantly increases the durability
of serum antibody responses against HA protein through
intranasal immunization
To investigate the impactof C48/80 on the persistence of antibody
responses, we monitored the dynamic changes of serum anti-HA IgG
titers over a 76-day period from the initial immunization. As shown in
Fig. 4, there are dramatic changes in GMT of serum IgG binding
antibodies against HA protein among the four groups over the course
of and post immunization. After each immunization, increasing levels
of antibody responses were found for animal group immunized with
either HA alone, HA plus C48/80, or HA plus CT. However, the
rate of increases was more profound for the latter two groups
compare to the first one. On day 21, one week after the third
immunization, the levels of antibody reached the peak for all three
groups but with more than 3 logs difference in antibody GMT
between the latter two and the first group (Fig. 4). In particular, when
antibody GMT in the HA alone group declined to below the
detection limit on day 45 after initial immunization, high levels of
antibody were still present in the other two groups despite an
approximately one log decline in absolute GMT compared to the
peak value (Fig. 4). More importantly, such high levels of antibody
responses in the two groups persisted over the following month
without appreciable decline, although HA plus CT group (27,857)
had about 3 times higher in absolute GMT compared with HA plus
C48/80 group (9,190). No changes in antibody levels were identified
for negative control animals throughout the study period. These
findings suggest that MC activator C48/80 can induce durable
antibody responses when used as an adjuvant against HA
recombinant protein through intranasal immunization.
High levels of binding antibodies against HA protein
boosted by C48/80 corresponds to the high levels of
neutralizing antibodies against A/California/04/2009 live
virus
Antibody binding activity does not always translate into
neutralizing capability. To study the neutralizing potential of
serum samples from immunized animals, we performed neutral-
ization assay based on A/California/04/2009 live virus and
MDCK cells in vitro. As the antibody binding activity is the
highest on day 21 after initial immunization, we used this time
point serum samples to evaluate their neutralization activities.
Serial two-fold dilutions of each serum samples from all four
groups were mixed separately with 100 TCID50 of A/California/
04/2009 live virus, and the neutralizing titers for each serum
sample, hence the GMT for each animal group, were assessed
based on presence or absence of cytopathic effect (CPE) 3 days
post infection. As shown in Fig. 5A, while HA alone group failed to
demonstrate detectable neutralizing activity, co-administration of
HA with C48/80 or CT resulted in significant higher levels of
neutralizing activity with GMT of 607 for the former and 1062 for
the latter. In addition, a significant correlation (P,0.0001) was
found between the antibody binding activities and neutralizing
capacity, reflected by high correlation coefficient (R
2) value of
0.9732 using a linear regression model (GraphPad Prism 5)
Figure 4. High and durable levels antibody responses in
animals immunized with HA plus C48/80 or plus CT compared
to those with HA alone or negative control PBS (n=5 per
group).
doi:10.1371/journal.pone.0019863.g004
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significantly boost binding as well as neutralizing antibodies
targeted on HA protein, therefore can potentially be a good
candidate for mucosal adjuvant.
Humoral responses boosted by C48/80 offer protective
immunity against lethal challenge by A/California/04/
2009 live virus
We further studied whether the high levels of antibody
responses boosted by C48/80 could provide any protective
immunity against lethal virus challenge. Twenty mice from each
study group were challenged intranasally with 1610
6 TCID50 of
live A/California/04/2009 on day 21, corresponding to one week
after the third immunization (Fig. 1). Of these, ten were scarificed
on day 5 after challenge to collect lung tissues for viral RNA
measurement and histopathological changes, while the remaining
ten were monitored for body weight loss and mortality over a two-
week period. The HA plus C48/80 group demonstrated high
protection rate with 9 out of 10 animals surviving up to 2 weeks
after challenged. No animals in HA plus CT group succumbed to
diseases. In contrast, all animals in the HA alone or in the negative
control group died 10 days after challenge (Fig. 6A). Furthermore,
the percent of survival was highly correlated with the percentage of
body weight recovery after challenge. As shown in Fig. 6B, despite
initial loss in body weight after challenge, animals in the group that
received HA plus C48/80 or plus CT began to recover on day 7
after challenge, while those in HA alone or negative control groups
continued to drop their weight until death. These findings
collectively suggest that high levels of antibody responses boosted
by C48/80 can offer protective immunity against diseases to the
level that is equivalent to that of CT.
Protected animals demonstrate minor histological
changes and decreased viral loads in lung tissues
To study the virologic and histopathologic changes in
immunized animals post challenge, lung tissues were collected
Figure 6. (A) Survival percentage of four groups of animals (n=10 per group) immunized with PBS, HA alone, HA plus C48/80 or HA plus CT. (B) Body
weight changes.
doi:10.1371/journal.pone.0019863.g006
Figure 5. (A) Comparison of serum neutralizing antibody activities against A/California/04/2009 live virus among the four groups of animals (n=6
per group) immunized with PBS, HA alone, HA plus C48/80 or HA plus CT. The numbers on the bar indicate the actual value of GMT. Star (*) indicates
the significant difference in neutralization titers between HA alone and HA plus C48/80 or plus CT (p,0.05). (B) Positive correlation between the
serum binding and neutralizing antibody activities in all animals tested(n=6 per group).
doi:10.1371/journal.pone.0019863.g005
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shows representative sections from the four animal groups. The
overall condition from HA plus C48/80 or CT group was quite
comparable to that found in the normal animals except for minor
degree of lymphocyte infiltration and aggregation around
pulmonary capillary as well as bronchiole wall. In contrast,
animals in HA alone or the negative control group exhibited
severe damage to the lung parenchyma, reflected by massive
lymphocyte infiltration, inflammatory hyperaemia, slight hemor-
rhage, edema, and exudative pathological changes. These findings
showed that immunization of HA together with C48/80 or CT
protected animals from lung damage after challenge with live A/
California/04/2009.
Further experiment was carried out to detect lung relative viral
loads by real time RT-PCR. Fig. 7B demonstrates a relative viral
load of 0.207 and 0.465 in mice that received HA alone and no
vaccination (negative control group) respectively. This translated
to 20,50 times higher viral loads than those in the HA plus C48/
80 or CT group. There was no significant difference, however,
found between the HA plus C48/80 and plus CT group. The
higher survival rates in these two groups were likely due to
significant reduced viral replication and replication related
inflammation.
Significant differences in IgG subclass & cytokine
production among different animal groups
The pattern of IgG subclasses reflects the subset of CD4+ T
helper (Th) cells polarized in immune responses leading to the
different mechanisms of host protection process [28,29]. Gener-
ally, IgG1 corresponds to Th2-biased responses, while IgG2a
corresponds to Th1-biased responses. To further investigate which
subset of Th cells was induced by HA plus C48/80 when
immunized intranasally, we monitored the GMT of serum HA-
specific IgG1, IgG2a, IgG2b and IgG3 in immunized animals on
day 21 after initial immunization (Fig. 1). As shown in Fig. 8, HA
plus C48/80 or plus CT induced marked increases for all IgG
subclasses compared to the HA alone group. Such increases were
in the order of 1–3 logs relative to that in the HA alone group
(Fig. 8). These findings suggest that C48/80, like that of CT, is
able to induce more balanced Th1/Th2 responses, consistent with
observed increases in antibody responses in immunized animals.
However, IgG1 titers were significantly higher than that of IgG2a,
IgG2b and IgG3 in all animal groups suggesting our recombinant
HA-based mucosal vaccine strategy, while quite balanced between
Th1/Th2, preferentially induces Th2-biased immune responses.
Furthermore, IgG2b titer was about 8-fold higher than IgG2a in
all immunized group, which was different from earlier report
where the reverse was observed when C48/80 was given
intradermally [30]. Lastly, the IgG3 levels were relatively low
and only became detectable when dilution factor was less than 200
in HA plus C48/80 or plus CT group while that in the HA alone
remained undetectable (Fig. 8).
To further investigate the ability of C48/80 in influencing
responses induced by HA recombinant vaccine, spleen were
harvested on day 21 after initial immunization (Fig. 1) and re-
stimulated with HA protein. Supernatants were collected 72 h later
and evaluated for various cytokines. As illustrated in Table 2,
supernatants from PBS or HA alone group had undetectable levels
of cytokines. Supernatant from HA plus C48/80, however, had
marked increased levels of IL-2, IL-6, and IL-10, whereas for HA
Figure 7. (A) Pathological analysis of the lung tissues from normal
animals or those immunized with PBS, HA alone, HA plus C48/80 or HA
plus CT after challenge with A/California/04/2009 live virus. (B)
Comparison of lung viral RNA between animals (n=6 per group)
immunized with PBS, HA alone, HA plus C48/80 or HA plus CT. The
numbers on the bar indicate the actual value of relative viral load. Star
(*) indicates the significant difference in viral RNA between HA alone
and HA plus C48/80 or plus CT (p,0.05).
doi:10.1371/journal.pone.0019863.g007
Figure 8. GMT of serum anti-HA IgG1, IgG2a, IgG2b, and IgG3
in animals (n=10 per group) immunized with HA alone, HA
plus C48/80 or HA plus CT on day 21 after initial immunization.
doi:10.1371/journal.pone.0019863.g008
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4. As IL-2 is a Th1 cytokine, whereas IL-6 and IL-10 are both Th2
cytokines, the cytokine profile is quite consistent with what is
expected, reinforcing the notion that C48/80 can induce balanced
Th1/Th2 responses. In particular, IL-6 is critical for the
development of follicular helper T (Tfh) cells for the activation
and maturation of B cells for antibody production [31,32]. Lastly, as
CT is able to induce high levelsof widearray of cytokines, this could
provide the reason why CT has such a strong adjuvant effects.
Discussion
In this study, we demonstrated that MC activator C48/80 had
strong adjuvant activity when co-administered with recombinant
HA protein through intranasal route. Vaccination with C48/80
significantly increased the serum IgG and mucosal surface IgA
antibody responses against HA protein. Such increases correlated
with stronger and durable neutralizing antibody activities, offering
protection to vaccinated animals from disease progression after
challenge with lethal dose of A/California/04/2009 live virus.
Furthermore, protected animals showed significant reduction in
lung virus titers, minimal structural alternation in lung tissues as
well as higher and balanced production of Th1 and Th2 cytokines
in the stimulated splenocytes compared to those without C48/80.
This study is the first to demonstrate that intranasal vaccination
with recombinant HA protein plus MC activator C48/80 is able to
induce protective immunity in mice. Although the dose and
immunization schedule need to be further optimized, especially for
human use, our results have provided the proof of principle for the
safety and efficacy of this novel vaccine strategy and its potential use
to overcome the short comings associated with conventional
influenza vaccine strategies [33]. In particular, using recombinant
HA protein instead of inactivated or attenuated viruses as
immunogen will eliminate the total dependence on embryonated
eggs and significantly shorten the time required for vaccine
production, as the production technology for recombinant protein
is becoming more standard and efficient. At the same time, it will
alsoavoidpotentialadverseeffectassociatedwithegg-basedproducts
such as hypersensitivity reactions and Guillain-Barre ´ syndrome
(GBS), a rare peripheral neuropathy leading to paralysis and in
severecasesrespiratoryfailure anddeath. Inaddition,astheC48/80
can significantly boost the immunogenicity of recombinant HA
protein through intranasal route, such immunization strategy can
provide protective immunity at the entry point of natural influenza
infectionandoffersaneedle-freeconveniencecomparedtoinjection-
based approach, especially when mass immunization is needed.
Our results have also confirmed the observations of others that
intranasal immunization is an effective and feasible immunization
strategy [34,35,36]. Among the mucosal adjuvants being studied,
Vibrio cholerae cholera toxin (CT) and Escherichia coli heat-labile
enterotoxin (LT) are among the most potent known to date
[37,38,39]. However, given their intrinsic toxic effect, neither of
them can be used for human vaccine in their native form. Despite
many attempts to improve the safety profile while maintaining its
mucosal adjuvant activity [40,41,42,43], a recent human phase I
trial with a mutant LT against human immunodeficiency virus
(HIV) and tuberculosis shown a transient facial nerve paralysis in
two trial participants, raising a serious concern on the safety profile
of this class of adjuvant and its future use in human vaccine [44]. In
contrast, MC activator C48/80 demonstrated much safer profile in
animals while showing comparable adjuvant activity with CT
[17,30], suggesting C48/80 may have potential to become a new
andlead class ofmucosaladjuvant forhumanuse.Thishypothesisis
supported by previous reports where C48/80 has been shown to
provide adjuvant activity to anthrax recombinant antigens immu-
nized either through intranasal or intradermal route without
apparent adverse effects [17,30]. Although the underlying mecha-
nism of C48/80’s adjuvant effect is not entirely clear, it has been
hypothesized that it can trigger mast cells to rapidly release
inflammatory mediators such as TNF, which in turn induce DCs
migration to draining lymph nodes, thereby boosting antigen-
specific responses [17,18,19,20,21]. In fact, recent studies also
suggest that mast cells can potentially facilitate the development of
adaptive immunity through its effector functions and/or by
releasing multiple cytokines, chemokines and growth factors
through various mechanisms [20,21,45,46]. Future studies, howev-
er, will be needed to delineate the mechanism of action and the
specificity of C48/80 in order to further develop it into a safe and
effective mucosal adjuvant for human use.
In summary, our findings indicate that the novel vaccine approach
combining recombinant HA and mucosal adjuvant C48/80 is safe
andeffectiveinelicitingprotectiveimmunityinmice.Itisastepcloser
to the ultimate success of recombinant influenza vaccine, offering
high speed and efficacy over the conventional strategies. Future
studies on the mechanism of action of C48/80 and potential
combination with other vaccine strategies such as prime and boost
approach may help to induce even morepotent and broader immune
responses against viruses from different groups.
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